Search
Search
Arshad M. Khanini, MD
Show Description +
Arshad M. Khanini, MD, presents the results of the phase 2 BOULEVARD trial, which studied the efficacy of RG7716 in patients with diabetic macular edema. RG7716 is the first bispecific antibody designed for intravitreal use.
Posted: 6/20/2018
Arshad M. Khanini, MD
Arshad M. Khanini, MD, presents the results of the phase 2 BOULEVARD trial, which studied the efficacy of RG7716 in patients with diabetic macular edema. RG7716 is the first bispecific antibody designed for intravitreal use.
Posted: 6/20/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of WOC: 2018.
Please log in to leave a comment.